Healthcare company Janssen Pharmaceutical Companies of Johnson & Johnson reported on Friday the receipt of the US Food and Drug Administration (FDA) accelerated approval for BALVERSA (erdafitinib) for treating adults with locally advanced or metastatic urothelial carcinoma (mUC), a form of bladder cancer.
BALVERSA ,which is now approved for locally advanced or metastatic urothelial carcinoma (mUC), which has susceptible fibroblast growth factor receptor (FGFR) or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, follows the US FDA's breakthrough therapy designation and priority review designation, added the company.
According to the company, BALVERSA (erdafitinib) is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC).
The company added that BALVERSA received accelerated approval based on results from its Phase 2 clinical trial (BLC2001, NCT02365597), a multicentre, open-label, single-arm study, of 87 patients with disease that had progressed on or after at least one prior chemotherapy and that had at least one of the following genetic alterations: FGFR3 gene mutations or FGFR gene fusions as determined by a clinical trial assay performed at a central laboratory. The results demonstrated a 32.2% objective response rate (ORR) as assessed by Blinded Independent Review Committee (BIRC).
Also, the company said it is offering BALVERSA and associated patient services through a single source specialty pharmacy provider, US Bioservices.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT